Alkermes (ALKS) Acquisitions (2011 - 2026)
Alkermes' (ALKS) quarterly Acquisitions came in at $2.1 billion in Q1 2026, up 1109181.38% quarter-over-quarter from -$188000.0 in Q4 2011.
Powered by 
Analysis
Alkermes (ALKS) Acquisitions (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Acquisitions for 2 consecutive years, with $2.1 billion the latest figure, recorded in Q1 2026.
- On a quarterly basis, Acquisitions changed N/A year-over-year to $2.1 billion in Q1 2026; TTM through Jun 2026 was $2.1 billion, a N/A change from a year earlier, with the FY2019 full-year figure at $8.9 million, changed N/A from the prior year.
- Acquisitions was $2.1 billion for Q1 2026 at Alkermes, up from -$188000.0 in the prior quarter.
- Over five years, Acquisitions peaked at $2.1 billion in Q1 2026 and troughed at $2.1 billion in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.93 Bn | 625.17 Bn | 17.26 Bn | -17.24 Bn |
| 2 | AbbVie | 443.06 Bn | 436.49 Bn | 12.70 Bn | - |
| 3 | Merck | 365.76 Bn | 358.62 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.47 Bn | 258.78 Bn | 11.24 Bn | -23.00 Mn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.36 Bn | 44.98 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 43.97 Bn | 43.97 Bn | - | - |
| 8 | Incyte | 25.42 Bn | 20.88 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.52 Bn | 18.86 Bn | 683.80 Mn | - |
| 10 | Alkermes | 7.58 Bn | 6.93 Bn | 397.90 Mn | - |